Barclays PLC Has $1.97 Million Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Barclays PLC lifted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 123.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,145 shares of the company’s stock after buying an additional 22,202 shares during the quarter. Barclays PLC owned about 0.14% of Disc Medicine worth $1,972,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Amalgamated Bank increased its stake in shares of Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after acquiring an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Disc Medicine in the second quarter valued at approximately $129,000. Quest Partners LLC acquired a new stake in Disc Medicine in the third quarter worth $131,000. Finally, Quantbot Technologies LP acquired a new stake in Disc Medicine in the third quarter worth $146,000. 83.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a report on Tuesday, November 5th. Wedbush reiterated an “outperform” rating and issued a $83.00 price objective on shares of Disc Medicine in a report on Monday, December 9th. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $66.00 to $110.00 in a research report on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research report on Monday, December 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, October 15th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $87.50.

Insider Activity

In other Disc Medicine news, Director William Richard White sold 7,136 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John D. Quisel sold 19,820 shares of Disc Medicine stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $63.14, for a total value of $1,251,434.80. Following the sale, the chief executive officer now directly owns 72,065 shares in the company, valued at $4,550,184.10. The trade was a 21.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,447 shares of company stock worth $4,134,585. Corporate insiders own 4.24% of the company’s stock.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $65.54 on Friday. Disc Medicine, Inc. has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -16.47 and a beta of 0.76. The stock has a fifty day moving average price of $60.14 and a 200-day moving average price of $51.28.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15. Research analysts predict that Disc Medicine, Inc. will post -4.05 EPS for the current fiscal year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.